# A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Source: https://onco.cc/trials/nct05503797/  
OnCo record `nct05503797` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Plixorafenib in advanced solid tumours, run by Fore Biotherapeutics, now recruiting.

## Summary

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations is a phase 2 interventional study registered as NCT05503797 by Fore Biotherapeutics, with 254 participants planned, started 2023-02-21 and due to reach its primary completion in 2027-12-31. Interventions recorded: Plixorafenib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05503797
- Phase: 2
- Setting: A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
- Sponsor: Fore Biotherapeutics
- Enrolled: 254

## Sources

- ClinicalTrials.gov NCT05503797: https://clinicaltrials.gov/study/NCT05503797

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05503797.json